Plethora of Clinical Trials Explore Gastric Cancer Treatments
The RAINFALL study (NCT02314117) was conducted to determine the benefit of adding ramucirumab to first-line chemotherapy regimens in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
The article discusses the growing landscape of clinical trials investigating various therapeutic options for gastric cancer, emphasizing targeted therapies such as ramucirumab, pembrolizumab, and trastuzumab, as well as emerging agents like dasatinib, lenvatinib, avelumab, and atezolizumab. It highlights key studies including the RAINFALL trial (NCT02314117) and the EPOC 1706 phase 2 study (NCT03609359), and outlines ongoing investigations like JAVELIN Gastric 100 (NCT02625610) and the DANTE study (NCT03421288).
Evaluating the efficacy of ramucirumab in combination with standard chemotherapy regimens is essential for improving survival outcomes and informing treatment guidelines for patients with metastatic gastric cancer, a disease with significant therapeutic challenges.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
- Current Treatment and Recent Progress in Gastric Cancer